Sign in Subscribe
Cancer research

Thromboembolic Events in Castration-Resistant Prostate Cancer Patients Receiving Oral Androgen Receptor Pathway Inhibitors

Strategic Insights

— 1 min read

A recent study published in The Prostate has investigated the association between thromboembolic events (TE) and castration-resistant prostate cancer (CRPC) patients receiving oral androgen receptor pathway inhibitors (ARPi) compared to those undergoing chemotherapy. The research used the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016, identifying a total of 2779 men diagnosed with CRPC.

Key Takeaways:

  • The study found that patients with pre-existing cardiovascular disease (CVD) treated with ARPi exhibited a significantly lower crude hazard ratio (HR) for TE compared to chemotherapy, with an HR of 0.39 (95% CI 0.27-0.58, p < 0.001).
  • When excluding patients with a prior history of TE, ARPi use remained non-significantly associated with new TE in the IPTW-adjusted competing risk analysis, highlighting the need for further investigation.
  • The research suggests that ARPi treatment may be a safer option for patients with CVD compared to chemotherapy.
  • The study used the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016, identifying a total of 2779 men diagnosed with CRPC.
  • The research was funded by the National Cancer Institute Grant 1K01CA230193, National Center for Advancing Translational Sciences UL1 Diversity Supplement Grant 3UL1TR002378-02S2, and other organizations.
  • Ewan K. Cobran from the Mayo Clinic was the lead author of the study, which included additional authors from various institutions.

Statistics:

  • 2779 men were identified with CRPC using the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016.
  • The study found a significantly lower crude hazard ratio (HR) for TE in patients with pre-existing CVD treated with ARPi compared to chemotherapy, with an HR of 0.39 (95% CI 0.27-0.58, p < 0.001).
  • When excluding patients with a prior history of TE, ARPi use remained non-significantly associated with new TE in the IPTW-adjusted competing risk analysis.

Sources:

  • Thromboembolic Events In Castration-resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors. The Prostate, 2025.
  • Researchers from College of Medicine and Science Report on Findings in Prostate Cancer (Thromboembolic Events In Castration-resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor ...). Health & Medicine Week. May 30, 2025; p 4625.

Read more